Eisai Files Application For Additional Indication Of Aricept For Lewy Body Dementia In Japan
This article was originally published in PharmAsia News
Eisai filed an application in Japan for an additional indication of Lewy Body Dementia for Alzheimer’s drug Aricept (donepezil).
You may also be interested in...
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.